跳至主要内容
临床试验/NCT00567593
NCT00567593已完成4 期

Gene Regulation by Thiazolidinediones

James Lewis1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2007年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
12
试验地点
1
主要终点
PDK4 mRNA

研究概览

简要总结

The purpose of this study is to determine the effect of rosiglitazone on the genes of the colon

详细描述

The primary aim of the study is to examine the effect of rosiglitazone (Avandia) on gene regulation in colonic epithelium in the absence of pathologic acute and chronic intestinal inflammation. The secondary aims are to determine the effect of rosiglitazone (Avandia) therapy on T cell activation and cytokine expression in the absence of pathologic acute and chronic intestinal inflammation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Capable of giving informed consent
  • Agrees to use a barrier method of birth control for the duration of the study

排除标准

  • History of inflammatory bowel disease
  • Has taken prescription or over the counter medications in the two weeks prior to enrollment
  • History of diabetes, heart failure, angina, hypertension, coronary heart disease, cancer, bleeding disorder, HIV, AIDS
  • Fasting LDL >160 mg/dl
  • History of smoking in the year prior to enrollment
  • Pregnant or breastfeeding

研究组 & 干预措施

Rosiglitazone

Other

Rosiglitazone; 8mg tablet once a day for 14 days

干预措施: Rosiglitazone (Drug)

结局指标

主要结局

PDK4 mRNA

时间窗: 14 days

次要结局

未报告次要终点

研究者

发起方
James Lewis
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

James Lewis

Professor of Medicine and Epidemiology

University of Pennsylvania

研究点 (1)

Loading locations...

相似试验